Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks

JAMA Psychiatry

Volumn 73, Issue 5, 2016, Pages 472-480

  Sherva, Richard ^a   Wang, Qian ^b   Kranzler, Henry ^c,d   Zhao, Hongyu ^b,e,f   Koesterer, Ryan ^a   Herman, Aryeh ^e   Farrer, Lindsay A ^a,g   Gelernter, Joel ^e,f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA Cooperative Studies Program Coordinating Center   (United States)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM BINDING PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CYTOCHROME P450 REDUCTASE; POTASSIUM; PROTEIN S100B; SOLUTE CARRIER FAMILY 35 MEMBER G1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CANNABIS ADDICTION; CHROMOSOME 3; COMORBIDITY; CUB AND SUSHI MULTIPLE DOMAINS 1 GENE; DISEASE ASSOCIATION; EUROPEAN AMERICAN; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PLEIOTROPY; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DNA MICROARRAY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; RISK;

ADULT; ALLELES; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84973346045     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.0036     Document Type: Article

References (50)

1. United Nation Office on Drugs and Crime (UNODC). Cannabis: A Short Review. https://www.unodc.org/documents/drug-prevention-and -treatment/cannabis-review.pdf. Published 2012. Accessed February 18, 2016.
2. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014; 371 (9): 879.
3. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Marijuana craving in the brain. Proc Natl Acad Sci U S A. 2009; 106 (31): 13016-13021.
4. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011; 17 (14): 1351-1358.
5. Wolfling K, Flor H, Grusser SM. Psychophysiological responses to drug-associated stimuli in chronic heavy cannabis use. Eur J Neurosci. 2008; 27 (4): 976-983.
6. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015; 72 (12): 1235-1242.
7. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004; 184: 110-117.
8. Power RA, Verweij KJ, ZuhairM, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014; 19 (11): 1201-1204.
9. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry. 2001; 158 (12): 2033-2037.
10. Lynskey MT, Glowinski AL, Todorov AA, et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry. 2004; 61 (10): 1026-1032.
11. Lynskey MT, Agrawal A, Henders A, Nelson EC, Madden PA, Martin NG. An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Res Hum Genet. 2012; 15 (5): 631-641.
12. Kendler KS, Ohlsson H, Maes HH, Sundquist K, Lichtenstein P, Sundquist J. A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men. Drug Alcohol Depend. 2015; 149: 49-54.
13. Agrawal A, Lynskey MT, Bucholz KK, et al. DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend. 2014; 134: 362-369.
14. Ehlers CL, Gilder DA, Gizer IR, Wilhelmsen KC. Heritability and a genome-wide linkage analysis of a type II/B cluster construct for cannabis dependence in an American Indian community. Addict Biol. 2009; 14 (3): 338-348.
15. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. AmJ Hum Genet. 2002; 71 (4): 877-892.
16. Han S, Yang BZ, Kranzler HR, et al. Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry. 2012; 72 (8): 637-644.
17. Verweij KJ, Vinkhuyzen AA, Benyamin B, et al. The genetic aetiology of cannabis use initiation: ameta-analysis of genome-wide association studies and a SNP-based heritability estimation. Addict Biol. 2013; 18 (5): 846-850.
18. Agrawal A, Lynskey MT, Hinrichs A, et al; GENEVA Consortium. A genome-wide association study of DSM-IV cannabis dependence. Addict Biol. 2011; 16 (3): 514-518.
19. Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry. 2014; 76 (1): 66-74.
20. Gelernter J, Sherva R, Koesterer R, et al. Genome-wide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. Mol Psychiatry. 2014; 19 (6): 717-723.
21. Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2014; 19 (1): 41-49.
22. Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of nicotine dependence in American populations: identification of novel risk loci in both African-Americans and European-Americans. Biol Psychiatry. 2015; 77 (5): 493-503.
23. Xie P, Kranzler HR, Yang C, Zhao H, Farrer LA, Gelernter J. Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder. Biol Psychiatry. 2013; 74 (9): 656-663.
24. National Center for Biotechnology Information. Study of Addiction: Genetics and Environment (SAGE) . phs000092.v1.p1. http://www.ncbi.nlm .nih.gov/projects/gap/cgi-bin/study.cgi?study-id =phs000092.v1.p1. Accessed March 4, 2016.
25. Bierut LJ, Strickland JR, Thompson JR, Afful SE, Cottler LB. Drug use and dependence in cocaine dependent subjects, community-based individuals, and their siblings. Drug Alcohol Depend. 2008; 95 (1-2): 14-22.
26. Edenberg HJ. The collaborative study on the genetics of alcoholism: an update. Alcohol Res Health. 2002; 26 (3): 214-218.
27. Bierut LJ, Madden PA, Breslau N, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet. 2007; 16 (1): 24-35.
28. National Center for Biotechnology Information. A Genome-wide Association Study of Heroin Dependence. phs000277.v1.p1. http://www.ncbi .nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study-id=phs000277.v1.p1. Accessed March 4, 2016.
29. Maloney E, Degenhardt L, Darke S, Mattick RP, Nelson E. Suicidal behaviour and associated risk factors among opioid-dependent individuals: a case-control study. Addiction. 2007; 102 (12): 1933-1941.
30. Pierucci-Lagha A, Gelernter J, Feinn R, et al. Diagnostic reliability of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) . Drug AlcoholDepend. 2005; 80 (3): 303-312.
31. Bucholz KK, Cadoret R, Cloninger CR, et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol. 1994; 55 (2): 149-158.
32. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42 (1): 121-130.
33. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010; 26 (17): 2190-2191.
34. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381 (9875): 1371-1379.
35. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing GWAS results by integrating pleiotropy and annotation. PLoS Genet. 2014; 10 (11): e1004787.
36. Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 2014; 216 (2): 277-285.
37. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 53: 23-34.
38. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013; 31: 105-114.
39. Yuan JP, ZengW, Huang GN, Worley PF, Muallem S. STIM1 heteromultimerizes TRPC channels to determine their function as store-operated channels. Nat Cell Biol. 2007; 9 (6): 636-645.
40. Krapivinsky G, Krapivinsky L, Stotz SC, Manasian Y, Clapham DE. POST, partner of stromal interaction molecule 1 (STIM1) , targets STIM1 to multiple transporters. Proc Natl Acad Sci U S A. 2011; 108 (48): 19234-19239.
41. Kraus DM, Elliott GS, Chute H, et al. CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol. 2006; 176 (7): 4419-4430.
42. SchizophreniaWorking Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511 (7510): 421-427.
43. Mao Z, Bonni A, Xia F, Nadal-Vicens M, GreenbergME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science. 1999; 286 (5440): 785-790.
44. Chevaleyre V, Heifets BD, Kaeser PS, Sudhof TC, Castillo PE. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha [published correction appears in Neuron. 2007 Jul 5; 55 (1): 169]. Neuron. 2007; 54 (5): 801-812.
45. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res. 2011; 128 (1-3): 66-75.
46. Eggan SM, Lazarus MS, Stoyak SR, et al. Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biol Psychiatry. 2012; 71 (2): 114-119.
47. Mathews RR, HallWD, Gartner CE. Depression and psychological distress in tobacco smokers and people with cannabis dependence in the National Survey of Mental Health andWellbeing. Med J Aust. 2011; 195 (3): S12-S15.
48. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009; 259 (7): 413-431.
49. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008; 13 (2): 264-275.
50. Issa BA. Cannabis use and psychiatric disorders. Neurosciences (Riyadh) . 2007; 12 (3): 265-266.